LIMN

Liminatus Pharma Inc

Jun 03 • 01:44PM ET

0.1587

-0.0362 -18.59 %

Healthcare • Biotechnology • USA • Nano • NASD

Today, 8:35 AMLiminatus Pharma enters warrant exercise deal to raise $1.9M, issue 20.7M new warrants at $0.18, pending stockholder approval

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX LNAI NEUP

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.40	Insider Own	47.93%	Shs Outstand	44.88M	Perf Week	-11.81%
Market Cap	7.12M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	23.37M	Perf Month	-25.50%
Enterprise Value	6.65M	PEG	-	EPS next Q	-	Inst Own	3.29%	Short Float	2.41%	Perf Quarter	-35.73%
Income	-11.00M	P/S	-	EPS this Y	-	Inst Trans	21.86%	Short Ratio	0.06	Perf Half Y	-83.55%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-788.65%	Short Interest	0.56M	Perf YTD	-73.98%
Book/sh	-0.00	P/C	3.73	EPS next 5Y	-	ROE	-	52W High	33.66 -99.53%	Perf Year	-97.00%
Cash/sh	0.04	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	0.13 20.27%	Perf 3Y	-98.43%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	14.25% 11.63%	Perf 5Y	-98.40%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-37.97%	Oper. Margin	-	ATR (14)	0.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.96	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.01	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.96	EPS Q/Q	-	SMA20	-15.47%	Beta	0.69	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-17.78%	Rel Volume	1.03	Prev Close	0.19
Employees	1	LT Debt/Eq	-	Earnings	-	SMA200	-82.88%	Avg Volume	9.84M	Price	0.16
IPO	May 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	6,764,014	Change	-18.59%

Today 08:30AM	Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds (GlobeNewswire) -18.59%
May-21-26 08:28PM	Liminatus Pharma Announces Nasdaq Delisting Notification (GlobeNewswire) +30.99% -31.14%
Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press)
Mar-17-26 08:08AM	Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody (GlobeNewswire)
Feb-17-26 08:44AM	Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering (GlobeNewswire) -31.86%
10:04AM	Loading…
Oct-30-25 10:04AM	Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation (GlobeNewswire)
Aug-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +22.66%
Aug-05-25 12:11PM	BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism (CoinDesk)
Jul-28-25 07:30AM	Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative (GlobeNewswire) -7.23%
Jul-25-25 08:31AM	Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies (GlobeNewswire)
Jul-24-25 08:31AM	Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy (GlobeNewswire) +30.91%
Jul-22-25 01:30PM	Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy (GlobeNewswire)

Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in Cerritos, CA.

L.L.M.Mr. Chris Kim J.D.

Chief Financial OfficerMr. Scott Dam

Chief Technology Officer & Member of Scientific Advisory BoardDr. Beom Kyu Choi

Chief Science Officer & Member of Scientific Advisory BoardDr. Byong Chul Yoo Ph.D.

Head of Research & Development and Member of Scientific Advisory BoardDr. Sang-jin Lee Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIMN

Liminatus Pharma Inc

Upgrade your Finviz experience